Bergolak tabs 0.5mg #8

Instruction for Bergolak

You can buy Bergolak online

Composition

One Bergolak tablet contains 500 μg of cabergoline and such auxiliary substances as anhydrous lactose, leucine and magnesium stearate.

Form of issue

Produced in white tablets, having oblong biconvex form and risk on one of the sides. In one carton, two or eight tablets can be placed in the polymer bottle.

pharmachologic effect

Has hypoprolactinemic and dopamine-stimulating effect.

Pharmacodynamics and pharmacokinetics

Bergolak is an ergoline derivative that is a dopamine receptor agonist and a prolactin secretagogue inhibitor.
The active substance is capable of stimulating dopamine D2 receptors on lacto- tropic pituitary cells, and high doses of the drug have a central dopaminergic effect. By inhibiting the synthesis of prolactin, its concentration in the blood decreases, which restores fertility and normalizes the menstrual cycle.
In women, the mechanism is to restore pulsatile secretion of gonadotropic hormones and release the luteinizing hormone in the middle of the cycle to eliminate anovulatory cycles and increase the concentration of estrogens, reduce the severity of hypoestrogenic symptoms accompanied by weight gain, fluid retention, osteoporosis and hyperandrogen symptoms with manifestations of acne and hirsutism.
In men, it eliminates the reduced libido associated with hyperprolactinemia, impotence due to an increase in testosterone concentration, and also reverses the development of the pituitary macroadenoma, eliminates gynecomastia and lactorrhea. This relieves symptoms such as headaches, disturbance of the visual and acuity fields, the functions of the cranial nerves and the endocrine lobe of the pituitary gland.
Reduces the concentration of prolactin within three hours after taking Bergolak and persists for 1-4 weeks in patients with hyperprolactinemia and 2-3 weeks in patients who suppress postpartum lactation. Reduced concentration of prolactin persists for 2-4 weeks. therapy.

Indications for use

The preparation is shown:
    with idiopathic hyperprolactinaemia or induced pituitary adenoma;
    to prevent or suppress postpartum lactation;
    for violations caused by hyperprolactinaemia, including for the treatment of amenorrhea, oligomenorrhoea, galactorrhea and anovulation;
    with the syndrome of an empty Turkish saddle, combined with hyperprolactinemia.

Contraindications

    Individual intolerance of the components of Bergolak, as well as derivatives of ergoalkaloids.
    Uncontrollable hypertension.
    Intolerance and impairment of absorption of galactose, glucose, and congenital deficiency of the enzyme lactase lapp.
    Violations of the functions of the cardiovascular and respiratory system as a result of fibrotic changes.
    The age group is under 16 years old.

Side effects

Emerging adverse reactions are most often dose-dependent, their manifestations are usually mild, transient or moderate. Occurring in the first 2 weeks of the drug, in the future they disappear on their own or require the abolition of therapy. On the part of various organs and systems, the following adverse reactions may occur:
    Nervous system, sensory organs: dizziness, headaches, visual disturbances, fatigue, drowsiness, development of depressive state, mania, nervousness, paresthesia, cases of fainting.
    Cardiovascular system: hot flushes, spasms of the vessels of the fingers, valvulopathy, orthostatic hypotension, asymptomatic decrease in blood pressure.
    Digestive system: nausea and vomiting, epigastric pain, constipation, gastritis, indigestion, impaired liver function.
    Other: allergic reactions, skin rash, pain in the mammary glands, dysmenorrhea.

Instructions for use Bergolak (Method and dosage)

Tablets are taken orally inside during a full meal.
Depending on the purpose of the application, different doses and regimens are prescribed:
    To prevent lactation in the postpartum period - a one-time dose of 1 mg (2 tab.) In the first day after childbirth.
    To suppress the already established lactation - 0.25 mg (0.5 tab.) Twice / day with an interval of 12 hours for 2 days to achieve a total dose of 1 mg.
    To reduce the risk of developing orthostatic hypotension - breast-feeding mothers are prescribed a single dose, not exceeding 0.25 mg.
    To treat disorders caused by hyperprolactinemia - an initial dose of 0.5 mg is recommended for 1 or 2 times a week, in the latter case, a break in several days is necessary. Further, until the necessary therapeutic effect is achieved, the weekly dose is gradually increased by 0.5 mg at monthly intervals, with the usual therapeutic dose being 1 mg / week, but may be in the range of 0.25 to 2 mg / week.
Attention! To reduce the likelihood of adverse reactions, it is recommended to start treatment with low-dose Bergolac, for example, with 0.25 mg / week, gradually increasing the dose to achieve the desired therapeutic effect. In order to improve the tolerability and reduce the risk of developing adverse side effects, a temporary reduction in the doses of the drug and their subsequent increase is permissible.

Overdose

It is accompanied by the following symptoms: nausea, vomiting, abdominal pain, constipation, lowering of blood pressure, orthostatic hypotension, headache, convulsions, severe asthenia, sweating, drowsiness, psychomotor agitation, up to psychosis and hallucinations.
For treatment, gastric lavage is performed, dopamine receptor antagonists are prescribed, among which are derivatives of Phenothiazine, Thioxanthene, Butirofenone, Metoclopramide.

Interaction

When applied simultaneously with the following substances and preparations, reactions occur:
    with antagonists of dopamine receptors (derivatives of phenothiazine, thioxanthene, butyrophenone, metoclopramide), the effect of cabergoline decreases;
    with macrolides possibly increasing the concentration of cabergoline in the blood.

Storage conditions

The temperature should not be more than 25 ° Celsius. It is recommended that you keep it out of the reach of children.
Shelf life - 2 years.

special instructions

Before using Bergolak, a complete examination of the pituitary gland functions should be performed.
Drugs with active substance - cabergoline should be used with caution in patients who have hemodynamic diseases of valves or who have taken drugs associated with valvulopathy.
Cabergoline is able in women to restore ovulation and fertility with hyperprolactinemic hypogonadism. Due to the fact that pregnancy can occur before the recovery of menstruation, it is recommended to conduct rapid tests for pregnancy at least 1 time in 4 weeks. during the amenorrhoea, and after recovery - each time with a delay in menstruation for 3 days or resort to barrier methods of contraception.

Reviews about Bergolak

A few reviews indicate the effectiveness of the drug Bergolak for the cessation of lactation. However, patients taking this hypoprolactinemic agent indicate unpleasant side reactions that accompany the first weeks of therapy.